-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Downgrades Ventyx Biosciences to Hold, Lowers Price Target to $14

Benzinga·01/08/2026 12:00:01
Listen to the news
Canaccord Genuity analyst Edward Nash downgrades Ventyx Biosciences (NASDAQ:VTYX) from Buy to Hold and lowers the price target from $16 to $14.